Search

Your search keyword '"Wiviott, Stephen D."' showing total 305 results

Search Constraints

Start Over You searched for: Author "Wiviott, Stephen D." Remove constraint Author: "Wiviott, Stephen D." Database Unpaywall Remove constraint Database: Unpaywall
305 results on '"Wiviott, Stephen D."'

Search Results

1. Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities

2. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

3. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

4. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

5. Hepatic Fat Changes with Antisense Oligonucleotide Therapy Targeting ANGPTL3

6. Abstract 14750: Performance of a Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of ASCVD: An Analysis of 60k Patients From 6 TIMI Randomized Trials

7. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

8. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 inhibition in Patients with Type 2 Diabetes

9. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 inhibition in Patients with Type 2 Diabetes

10. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

11. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus

12. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes

13. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

14. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58

15. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

16. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

17. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses from DECLARE-TIMI 58

18. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses from DECLARE-TIMI 58

19. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

20. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

21. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

22. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

23. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes

24. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

25. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

26. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

27. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

28. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

29. Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

30. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58

31. Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

32. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

33. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

34. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

35. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48

36. Abstract 13846: Prognostic Value of Echocardiographic Markers of Diastolic Dysfunction for Heart Failure in Overweight and Obese Patients in CAMELLIA-TIMI 61

37. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

39. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

40. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

41. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

42. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial

43. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

44. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

45. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

46. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

47. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

48. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

49. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

50. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Catalog

Books, media, physical & digital resources